INAL RESEARCH Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study

被引:5
|
作者
Kang, D. -W. [1 ]
Park, S. -K. [2 ]
Yu, Y. L. [3 ]
Lee, Y. [4 ]
Lee, D. H. [5 ]
Kang, S. [3 ,6 ,7 ,8 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea
[3] Natl Canc Ctr, Ctr Gynecol Canc, Res Inst & Hosp, Goyang, South Korea
[4] Natl Canc Ctr, Dept Internal Med, Goyang, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, Goyang, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
[8] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
关键词
next-generation sequencing; single-gene testing; non-small-cell lung cancer; distant metastasis; real-world evidence;
D O I
10.1016/j.esmoop.2023.102200
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite the growing use of next-generation sequencing (NGS) in the management of advanced non-smallcell lung cancer (NSCLC), there is little evidence that its use leads to improved clinical outcomes. This study aimed to compare the effectiveness of NGS with that of single-gene testing (SGT) alone in patients with advanced NSCLC. Materials and methods: This was a retrospective cohort study conducted on patients diagnosed with advanced lung adenocarcinoma between 2017 and 2018 from a nationwide, population-based database. We identified patients who had SGT exclusively (SGT group) or underwent upfront NGS or NGS following SGT as an initial evaluation (NGS group). Patients were followed up until death or the end of the study (31 December 2019). The adjusted hazard ratio (aHR) for death was estimated using the Cox proportional hazards model. The factors affecting the adoption of NGS were identified. Results: Of 8566 patients diagnosed with advanced lung adenocarcinoma, 402 and 6932 patients were assigned to the NGS and SGT groups, respectively. More NGS was carried out in younger patients, those with higher incomes, and those living in urban areas. After balancing these confounders through matching, no difference was observed in the median overall survival and risk of death between the NGS and SGT groups [18.5 versus 19.7 months, log-rank P 1/4 0.783; aHR 0.98, 95% confidence interval (CI) 0.84-1.14, respectively]. Only in a subgroup for whom epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitors were not indicated, NGS was associated with better survival outcomes (14.1 versus 9.0 months, log-rank P 1/4 0.006; aHR 0.82, 95% CI 0.69-0.97). Conclusions: In the real world, NGS for all-comers in patients with advanced NSCLC did not increase survival outcomes. When health care resources to support equal access to NGS are limited, upfront SGT followed by NGS may be a more efficient strategy
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Clinical impact of plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC)
    Bonanno, L.
    Pavan, A.
    Ferro, A.
    Calvetti, L.
    Frega, S.
    Pasello, G.
    Aprile, G.
    Guarneri, V.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2019, 30 : 577 - 577
  • [32] Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing
    El Zaitouni, Sara
    Laraqui, Abdelilah
    Ghaouti, Meriem
    Benzekri, Asmae
    Kettani, Fouad
    Boustany, Youssra
    Benmokhtar, Soukaina
    Alaoui, Hafsa Lamrani
    El Annaz, Hicham
    Abi, Rachid
    Tagajdid, Mohamed Rida
    El Kochri, Safae
    El Mchichi, Bouchra
    Bouaiti, El Arbi
    Lahlou, Idriss Amine
    El Hassani, Rabii Ameziane
    Ennibi, Khalid
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [33] Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in the US Community Setting
    Vidal, Gregory A.
    Jain, Neha
    Fisher, Aaron
    Sheinson, Daniel
    Lofgren, Katherine T.
    Ma, Esprit
    Yu, Elaine
    Comment, Leah
    Miksad, Rebecca
    Sincan, Murat
    Martin, Richard Lewis
    Zuniga, Richard
    Daniel, Davey
    JCO ONCOLOGY PRACTICE, 2024, 20 (03) : 370 - 377
  • [34] Prospective mutational characterization of Japanese patients with non-small cell lung cancer by next-generation sequencing
    Kenmotsu, Hirotsugu
    Koh, Yasuhiro
    Serizawa, Masakuni
    Isaka, Mitsuhiro
    Maniwa, Tomohiro
    Murakami, Haruyasu
    Mori, Keita
    Endo, Masahiro
    Nakajima, Takashi
    Ohde, Yasuhisa
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    CANCER RESEARCH, 2014, 74 (19)
  • [35] Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non-small-cell lung cancer
    Zheng, Songbai
    Wang, Xiaodan
    Fu, Ying
    Li, Beibei
    Xu, Jianhua
    Wang, Haifang
    Huang, Zhen
    Xu, Hui
    Qiu, Yurong
    Shi, Yaozhou
    Li, Kui
    BIOENGINEERED, 2021, 12 (01) : 791 - 802
  • [36] Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer
    Cui, Shaohua
    Zhang, Wei
    Xiong, Liwen
    Pan, Feng
    Niu, Yanjie
    Chu, Tianqing
    Wang, Huimin
    Zhao, Yizhuo
    Jiang, Liyan
    ONCOTARGET, 2017, 8 (02) : 2771 - 2780
  • [37] Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing
    Wang, Buhai
    Fan, Yaqin
    Zhang, Liying
    Liu, Liqin
    Ma, Yutong
    Ma, Xiaosong
    Huang, Yuxiang
    Wu, Yinxia
    Liang, Yichen
    Xu, Yang
    Wu, Xue
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [38] Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing
    Wang, Buhai
    Fan, Yaqin
    Zhang, Liying
    Liu, Liqin
    Ma, Yutong
    Ma, Xiaosong
    Huang, Yuxiang
    Wu, Yinxia
    Liang, Yichen
    Xu, Yang
    Wu, Xue
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [39] Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group
    Malapelle, Umberto
    Delle Donne, Alessandro
    Pagni, Fabio
    Fraggetta, Filippo
    Rocco, Elena Guerini
    Pasello, Giulia
    Perrone, Giuseppe
    Pepe, Francesco
    Vatrano, Simona
    Pignata, Sandro
    Pinto, Carmine
    Pruneri, Giancarlo
    Russo, Antonio
    Parra, Hector J. Soto
    Vallone, Stefania
    Marchetti, Antonio
    Troncone, Giancarlo
    Novello, Silvia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 193
  • [40] Evaluation of the Mutation Profile via Next-Generation Sequencing in a Turkish Population with Non-small Cell Lung Cancer
    Cetin, Nesibe Kahraman
    Erdogdu, Ibrahim Halil
    Bozkurt, Emin
    Meteoglu, Ibrahim
    BALKAN MEDICAL JOURNAL, 2021, 38 (06) : 382 - 391